All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 2, 2023

ASH

Home » Topics » Conferences » ASH
  • Dec. 15, 2022

    Conference data for Dec. 15, 2022: ASH

    New and updated clinical data presented by biopharma firms at the American Society of Hematology annual meeting and exposition, including: Amgen, Beigene, Novartis, Pharming.
  • Dec. 14, 2022

    Conference data for Dec. 14, 2022: ASH

    New and updated clinical data presented by biopharma firms at the American Society of Hematology annual meeting and exposition, including: Alx, Avencell, Atara, Cellectis, Coimmune, Corvus, Disc, Elixirgen, Galapagos, Genentech, Glycomimetics, Gracell, GSK, Harpoon, Imago, Immunogen, In8bio, Incyte, Innate, Innovent, Janssen, Junshi, JW, Karyopharm, Keros, Kite, Kura, Lava, Loxo, Maat, Magenta, Mendus, Nektar, Nurix, Oncternal, Orca, Orchard, Oryzon, Pfizer, Prothena, Regeneron, Roche, Rocket, Ryvu, Seagen, Sellas, Starpharma, Sumitomo, Sutro, Syndax, Syntrix, Syros, Taiho, Tessa, Treadwell, Vincerx, X4, Xencor.
  • Dec. 13, 2022
    By Tamra Sami

    ASH 2022: One-time infusion CSL’s Hemgenix gene therapy shows durable response for hemophilia B

    After gaining U.S. FDA priority approval for the first gene therapy to treat hemophilia B, CSL Ltd. reported long-term data from the pivotal HOPE-B trial that showed a single infusion of Hemgenix (etranacogene dezaparvovec-drlb) generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding.
Read More

Authors

  • Brian Orelli
  • Michael Fitzhugh
  • Randy Osborne
  • Anette Breindl
  • Cormac Sheridan
  • Tamra Sami
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing